Editorial Board

Our editorial board is comprised of cancer experts, organized primarily by disease focus. If you are interested in getting involved, please feel free to contact us with any questions or inquiries, at contact @ hemonc.org.

Editor-in-Chief

Peter C. Yang, MD Boston, MA, USA

Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts.

Deputy Editor

Andrew J. Cowan, MD Seattle, WA, USA LinkedIn

Dr. Cowan is board certified in Hematology and Medical Oncology; he is the Interim Clinical Director of the myeloma service at the Fred Hutch Cancer Center. He is an associate professor at the University of Washington.

Associate Editors

Cancer Registries
	Mary Mesnard, BS, CTR LinkedIn	Ms. Mesnard is a senior study director at Westat and was formerly with the State of Maryland's central cancer registry.
Evidence-based Oncology
	Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO, USA	Dr. Schoen is board certified in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University.
Pediatric Hematology/Oncology
	Wayne H. Liang, MD, MS, FAMIA Emory University Atlanta, GA, USA LinkedIn	Dr. Liang is board certified in Pediatrics, Pediatric Hematology-Oncology, and Clinical Informatics; he practices at Children’s Healthcare of Atlanta. He is an Assistant Professor of Pediatrics at Emory University.
Radiation Oncology
	Danielle S. Bitterman, MD Dana-Farber Cancer Institute Boston, MA, USA LinkedIn	Dr. Bitterman is board certified in Radiation Oncology; she practices at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. She is an Assistant Professor of Radiation Oncology at Harvard Medical School.
Supportive Oncology
	Maryam B. Lustberg, MD, MPH Yale University New Haven, CT, USA LinkedIn	Dr. Lustberg is board certified in Medicine and Medical Oncology; she is the director of the Breast Center at Smilow Cancer Hospital and chief of Breast Medical Oncology at Yale Cancer Center. She is an Associate Professor of Internal Medicine (Medical Oncology) at Yale University. She is the co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the 2022 president of the Multinational Association of Cancer Supportive Care (MASCC)

Regional Associate Editors

Asia
Europe and United Kingdom
	Mark P. Lythgoe, MBBS, PharmD Imperial College London London, England, UK LinkedIn	Dr. Lythgoe is a medical oncologist, clinical pharmacist, and health services researcher. His work involves analyzing cancer drug approvals and regulatory pathways.
North Africa and Middle East
Oceania
	Georgina Kennedy, PhD Ingham Institute for Applied Medical Research Sydney, NSW, Australia LinkedIn	Dr. Kennedy is a health data infrastructure specialist and data engineer. Her work involves harmonizing systemic anticancer therapy standards, including the eviQ resource of evidence-based, consensus driven cancer treatment protocols.
Latin America
Sub-Saharan Africa

Section Editors

Breast Oncology
	TBA
Dermatologic Oncology
	Elizabeth Buchbinder, MD Boston, MA, USA LinkedIn	Dr. Buchbinder is board certified in Medical Oncology; she is a senior physician at the Dana-Farber Cancer Institute. She is an Assistant Professor of Medicine at Harvard Medical School.
Endocrine Oncology
	Unfilled	If you are interested in this role, please contact us at contact @ hemonc.org.
Gastrointestinal Oncology, Intestinal
	Travis Zack MD, PhD San Francisco, CA, USA	Dr. Zack is a senior hematology/oncology fellow at the University of California, San Francisco.
Gastrointestinal Oncology, Extraintestinal
	Eric I. Marks, MD Boston, MA, USA	Dr. Marks is board certified in Medical Oncology; he practices at Boston Medical Center and is an Assistant Professor of Medicine at Boston University School of Medicine.
Genitourinary Oncology
	Ali Raza Khaki, MD Palo Alto, CA, USA	Dr. Khaki is board certified in Hematology and Medical Oncology; he practices at Stanford Health Care. He is a a Clinical Assistant Professor of Oncology at Stanford University School of Medicine.
Gynecologic Oncology
	Alaina J. Brown, MD, MPH Nashville, TN, USA	Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Assistant Professor of Obstetrics and Gynecology at Vanderbilt University.
Head & Neck Cancer
	Jennifer H. Choe, MD, PhD Nashville, TN, USA LinkedIn	Dr. Choe is board certified in Internal Medicine and Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center, where she is the Head and Neck Medical Oncology Disease Team Lead and directs the clinical trials research program in the Division of Hematology and Oncology within the Department of Medicine at Vanderbilt University Medical Center. She is an Assistant Professor of Medicine at Vanderbilt University and specializes in cancers of the head and neck, thyroid, and non-melanoma skin cancers.
Mesothelioma
	Marjorie G. Zauderer, MD, MS, FACP New York, NY, USA	Dr. Zauderer is board certified in Medical Oncology; she is co-director of the mesothelioma program at Memorial Sloan Kettering Cancer Center.
Neuro-Oncology
	Seema Nagpal, MD Palo Alto, CA, USA	Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a Clinical Professor of Neurology at Stanford University
Sarcoma
	Elizabeth J. Davis, MD Nashville, TN, USA	Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center and is the medical director of the Clinical Trials Office. She is an associate professor at Vanderbilt University.
Thoracic Oncology
	Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA	Dr. Kulkarni is board certified in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota.
Acute Leukemias
	Ashwin Kishtagari, MD Vanderbilt University Nashville, TN, USA	Dr. Kishtagari is board certified in Internal Medicine and Medical Oncology; he practices at Vanderbilt University Medical Center. He is an Assistant Professor of Medicine (Hematology/Oncology) at Vanderbilt University.
Myeloproliferative Neoplasms and Myelodysplastic Syndromes
	Sanjay R. Mohan, MD, MSCI Nashville, TN, USA	Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.
Aggressive Lymphomas & Lymphoproliferative disorders
	Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT, USA	Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University.
Indolent Lymphomas
	Sanjai Sharma, MD Visalia, CA, USA	Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center.
Plasma Cell Dyscrasias
	Samuel M. Rubinstein, MD University of North Carolina Chapel Hill, NC, USA LinkedIn	Dr. Rubinstein is board certified in Hematology and Medical Oncology; he is a clinical assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias.
T-cell and NK-cell neoplasms
	Bhagirathbhai Dholaria, MBBS Nashville, TN, USA	Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University.
Histiocytic Disorders
	Gaurav Goyal, MBBS UAB Birmingham, AL, USA	Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at the O'Neal Comprehensive Cancer Center at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham).
Pediatric Blastomas & Extracranial Germ Cell Tumors
	Elaine M. Fan, MD, MS Wichita, KS, USA	Dr. Fan is an Assistant Professor of Pediatrics at the University of Kansas and practices at Wesley Medical Center. She is particularly interested in applying clinical informatics to improve clinical workflow efficiency, enhance provider and patient experience and, ultimately, improve health outcomes in pediatrics and pediatric hematology-oncology. Dr. Fan is board-certified in Pediatrics and board-eligible in Pediatric Hematology-Oncology.
Pediatric Leukemia & Lymphoma
	David Noyd, MD, MPH University of Washington Seattle, WA, USA	Dr. Noyd is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at Seattle Children's Hospital. He is an Assistant Professor of Pediatrics at the University of Washington.
Pediatric Neuro-Oncology & Solid Tumors
	Nicole M. Wood, DO University of Missouri Kansas City, MO, USA LinkedIn	Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri.
Transplant
	Talal Hilal, MD Mayo Clinic Phoenix, AZ, USA	Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at Mayo Clinic Arizona. He is an assistant professor at the Mayo Clinic.
Classical Hematology
	Benjamin Tillman, MD Vanderbilt University Nashville, TN, USA	Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an Assistant Professor of Medicine (Hematology/Oncology)
Clinical Pharmacology
	Austin Fitts, PharmD National Cancer Institute Silver Springs, MD, USA LinkedIn	Dr. Fitts is a Postdoctoral Fellow at the National Cancer Institute.
Living Systematic Reviews
	Irbaz Bin Riaz, MD, PhD, MS Mayo Clinic Phoenix, AZ, USA	Dr. Riaz is board certified in Internal Medicine and Medical Oncology; he is an Assistant Professor of Medicine at Mayo Clinic, Arizona.

Page Editors

• Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA, USA)
  • Chronic lymphocytic leukemia

• Brianna Bakow, MD (Brigham and Women's Hospital, Boston, MA, USA)
  • Antiphospholipid antibody syndrome

• Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY, USA)
  • Renal cell carcinoma
    • Clear cell renal cell carcinoma
    • Non-clear cell renal cell carcinoma
      • Papillary renal cell carcinoma
      • Sarcomatoid renal cell carcinoma
    • RCC, VHL-associated

• Michael J. Glover, MD (Stanford University, Palo Alto, CA, USA)
  • Urothelial carcinoma
    • Bladder cancer
  • Testicular cancer

• Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO, USA)
  • Prostate cancer

• Matthew Hadfield, DO (Lifespan/Brown University, Providence, RI, USA)
  • Immunotherapy toxicity management

• C. Beau Hilton, MD (Vanderbilt University, Nashville, TN, USA)
  • Head and neck cancer
  • Nasopharyngeal carcinoma
  • Oropharyngeal cancer, HPV-positive

• Shalin Kothari, MD (Yale University, New Haven, CT, USA)
  • Mantle cell lymphoma

• Mary L. Kwok, MD, FACP (Fred Hutch Cancer Center, Seattle, WA, USA)
  • Multiple myeloma, relapsed-refractory

• Emily A. Mann, MD (Boston University, Boston, MA, USA)
  • Gallbladder cancer

• Eric I. Marks, MD (Boston University, Boston, MA, USA)
  • Gastrointestinal stromal tumor

• Francesca Montanari, MD (Yale University, New Haven, CT, USA)
  • Post-transplant lymphoproliferative disorder

• Ryan H. Nguyen, DO (University of Illinois at Chicago, IL, USA)
  • Melanoma

• Michael K. Rooney, MD (MD Anderson Cancer Center, Houston, TX, USA)
  • Radiotherapy toxicity management

• Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX, USA)
  • Non-small cell lung cancer

• Leyre Zubiri, MD, PhD (Massachusetts General Hospital, Boston, MA, USA)
  • Immunotherapy toxicity management

COI Disclosures

Please see our conflict of interest page for more details. Disclosures here are for COI within 24 months of the date of disclosure unless otherwise noted.

Name	Research funding (to institution)	Other (honoraria, travel support, significant ownership interests, etc.)	Date of disclosure
Jon Arnason	Nothing to disclose	Speaker: Bristol-Myers Squibb	2023-06-28
Brianna Bakow	Nothing to disclose	Nothing to disclose	2023-08-27
Danielle S. Bitterman	Nothing to disclose	Nothing to disclose	2023-08-03
Alaina J. Brown	NIH	Nothing to disclose	2022-08-03
Elizabeth Buchbinder	NIH; Clinical trial support from Eli Lilly, Novartis, Checkmate Pharmaceuticals, Genentech/Roche, and Bristol-Myers Squibb.	Consulting as an advisory board member for Novartis, Instil Bio, Nektar, Xilio Therapeutics, Sanofi, Merck, Iovance Biotherapeutics; Employment (family member): Alexion Pharmaceuticals, Takeda.	2023-08-03
Jennifer H. Choe	Institutional research funding: Alx oncology, Merck Sharp & Dohme, Arcus Biosciences	Advisory Board and consulting: Eisai, Exelixis, Merck Sharp & Dohme, Coherus Biosciences	2023-09-29
Andrew Cowan	Abbvie, Nektar, Harpoon, Janssen, Adaptive, Sanofi, BMS, Celgene	Consultancy: Abbvie, BMS, Secura Bio, EUSA, GSK	2024-03-04
Elizabeth J. Davis	Trial funding: Karyopharm, Bristol Myers Squibb, Incyte, Actuate, InhibRx, Top Alliance BioSciences, Genentech, Five Prime Therapeutics	Consulting/Advisory Board: Deciphera, Aadi Honoraria: MJH Life Sciences Speakers' Bureau: Physicians' Education Resource	2023-01-03
Bhagirathbhai Dholaria	Research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir, NCI, Atara, Gilead, Molecular templates, BMS, AstraZeneca, Adicet	Consulting/Advisory Board: Janssen, Pluri Biotech, Boxer Capital; Consultation/travel funds: Ellipsis pharma, Lumanity, Autolus, Acrotech, ADC therapeutics	2023-09-09
Elaine Fan	Nothing to disclose	Consulting: Westat	2023-09-09
Austin Fitts	Nothing to disclose	Consulting: Westat	2023-01-03
Teja Ganta	Nothing to disclose	Other: Epic Systems, Analog Devices	2023-09-04
Michael J. Glover	Nothing to disclose	Nothing to disclose	2023-04-15
Gaurav Goyal	NIH/NCI	Consultancy: 2nd.MD; Royalties: UpToDate Inc; Advisory Board: Opna Bio LLC, Seagen	2023-09-10
Laura Graham	Nothing to disclose	Nothing to disclose	2023-09-11
Matthew Hadfield	Nothing to disclose	Nothing to disclose	2023-08-07
Talal Hilal	NIH/NCI	Nothing to disclose	2023-09-11
C. Beau Hilton	Nothing to disclose	Nothing to disclose	2023-10-03
Ali R. Khaki	Janssen, 23andMe	Consulting/Advisory Board: Seagen/Astellas Travel: BCAN; SABCS Honoraria: Onclive CME	2023-09-01
Ashwin Kishtagari	Nothing to disclose	Consulting/Advisory Board: CTI BioPharma	2023-08-03
Shalin Kothari	Nothing to disclose	Nothing to disclose	2023-08-10
Amit Kulkarni	Research Funding to Institution: Astra Zeneca	Consulting/Advisory Board: Genentech, Exelixis; Stock and Other Ownership Interests: Fate Therapeutics, Merck, Exact Sciences, Gilead Sciences, Mirati Therapeutics, Novavax.	2023-08-03
Mary L. Kwok	BeiGene	Nothing to disclose	2023-06-28
Wayne H. Liang	Nothing to disclose	Consulting/Advisory Board: Westat	2021-11-10
Maryam Lustberg	Nothing to disclose	Consulting/Advisory Board: Pfizer, Gilead, Novartis, Eli Lilly, AstraZeneca	2023-07-04
Mark P. Lythgoe	Nothing to disclose	Nothing to disclose	2023-10-29
Emily A. Mann	Nothing to disclose	Nothing to disclose	2023-08-30
Eric Marks	Research funding: Merck	Consulting/Advisory Board: Sermo, Medscape, Brand Institute, M3	2023-06-28
Mary Mesnard	Nothing to disclose	Nothing to disclose	2023-08-03
Sanjay R. Mohan	Research funding: NCCN, Ichnos, Incyte, Kartos, Karyopharm, Taiho	Nothing to disclose	2023-08-24
Francesca Montanari	Nothing to disclose	Nothing to disclose	2023-06-29
Seema Nagpal	Trial funding: Agios, PharmAbcine, Insightec, Berg, Inovio	Consulting/Advisory Board: EnClear, SeaGen, Novocure Steering Committee, Nurix, Biocept Steering Committee; Guidelines: NCCN CNS committee, ARS-AUC CNS committee, ASTRO Brain metastases guideline committee	2022-04-22
Ryan Nguyen	Exelixis (research funding to institution)	Genomeweb (honoraria), Merck (speaker's bureau)	2023-09-16
David Noyd	Nothing to disclose	Consulting/Advisory Board: Westat	2023-09-11
Irbaz Bin Riaz	NIH/NCI	Nothing to disclose	2023-08-10
Michael K. Rooney	Nothing to disclose	Nothing to disclose	2023-09-13
Samuel R. Rubinstein	Nothing to disclose	Consulting/Advisory Board: Janssen, Sanofi, LAVA therapeutics, EUSA pharma, and Roche Diagnostics	2022-09-10
Martin Schoen	St. Louis Veterans Affairs Medical Center, Congressionally Directed Medical Research Program	Consulting/Advisory Board: Doximity, Pfizer	2023-08-11
Sanjai Sharma	Nothing to disclose	Nothing to disclose	2023-09-11
Eric K. Singhi	Nothing to disclose	Consulting/Advisory Board: AstraZeneca	2023-08-10
Benjamin F. Tillman	Nothing to disclose	Nothing to disclose	2023-01-29
Nicole M. Wood	Nothing to disclose	Consulting/Advisory Board: Westat	2023-08-07
Peter C. Yang	Nothing to disclose	Ownership: HemOnc.org Stock: Merck, Pfizer	2023-10-12
Travis Zack	Nothing to disclose	Nothing to disclose	2023-09-05
Marjorie Zauderer	Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer.	In the last 3 years, Dr. Zauderer has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated.	2023-08-08
Leyre Zubiri	Nothing to disclose	Honoraria: Merck	2022-08-22